Administration of Zoledronic Acid in Newly Diagnosed Multiple Myeloma
Initial Dosing Scheme
- The American Society of Clinical Oncology recommends that zoledronic acid be administered every 3-4 weeks initially, with the option to change to every 3 months (12 weeks) after 2 years in patients with stable disease or in response who are on maintenance therapy 1, 2
- The standard dose is 4 mg intravenously over at least 15 minutes every 3-4 weeks, which can be adjusted based on renal function 3, 1, 4
Transition to Less Frequent Dosing
- After 2 years of treatment, the American Society of Clinical Oncology recommends considering an administration interval of every 3 months (12 weeks) in patients with stable disease or in response who are on maintenance therapy 1, 2
- Less frequent dosing has been evaluated and should be considered specifically in patients with responsive or stable disease 1, 2, 6
Total Duration of Treatment
- Treatment with bisphosphonates should continue for up to 2 years 1, 2, 5
- After 2 years, the physician should consider stopping bisphosphonates in patients with stable disease or in response 1, 5
Renal Function Adjustments
- For patients with pre-existing renal insufficiency, dose adjustments are required 1, 2
- The dose should be adjusted based on creatinine clearance, with a dose of 4 mg for creatinine clearance >60 mL/min, 3.5 mg for 50-60 mL/min, 3.3 mg for 40-49 mL/min, and 3.0 mg for 30-39 mL/min 7, 5
Monitoring Requirements
- Serum creatinine should be measured before each dose 1, 5, 8, 9
- Intermittent evaluation (every 3-6 months) for albuminuria in all patients is recommended 3, 1, 5, 9
Management of Renal Deterioration During Treatment
- If renal deterioration occurs during therapy, the physician should suspend zoledronic acid if creatinine increases ≥0.5 mg/dL (normal baseline function) or ≥1.0 mg/dL (abnormal baseline function) 9
- Treatment can be re-initiated when creatinine returns to within 10% of baseline value 9